Glycans (monosaccharides and oligosaccharides) and their conjugates (glycoproteins, glycolipids, and proteoglycans) are structurally diverse biomolecules that are involved in many biological processes of health and disease. The structural diversity of glycans and glycoconjugates is owed to their monosaccharide composition, anomeric state, glycosidic linkage, modification (phosphorylation, sulfation, acetylation, etc.) and aglycone (protein, lipid, etc.). These diverse structures are controlled by complex glycosylation processes in cells, which are mediated by various glycosyltransferases and glycosidases. Glycosylation processes can be chemically regulated by inhibition of glycosyltransferases or glycosidases with natural and synthetic molecules. Treatment of cells with inhibitors of these enzymes results in the production of glycans or glycoconjugates containing missing or altered glycan chains. This approach is highly useful for examining the potential functional role(s) of glycans and glycoconjugates in cells or tissues, and in biological processes of health and disease. Eventually, it will provide novel mechanisms for disease treatment. This review highlights recent developments in chemical regulation of glycosylation processes with specific targets including: inhibition of (1) Nglycosylation, (2) O-glycosylation, (3) O-linked GlcNAc glycosylation, (4) proteoglycan biosynthesis, (5) glycolipid biosynthesis, and (6) terminal glycosylation. The goal of this review is to provide researchers with more competent choices in their research and lay a foundation on which continued advancements can be made to promote further explorations in glycoscience and biomedical research and applications.
and in vivo provides a powerful approach for studying glycan and glycoconjugate functions and mechanisms and discovering novel therapeutic targets as well (6, 7) . Glycosyltransferases catalyze the synthesis of glycans and glycoconjugates. The expression and activity of these enzymes are controlled at the transcription, translation and post-translation levels. Therefore, glycosylation can be regulated at multiple levels (8) , such as transcriptional (9) , posttranscriptional (10) , and post-translational (11) regulation. Gene silencing or knockout of a glycosylation processing enzyme is often used by molecular biologists to hinder glycan biosynthesis for examining the function of endogenous glycan chains. However, it may knock out all glycan biosynthesis and thus cause multiple effects, making it difficult to attribute a specific biological role to a specific glycan structure in a spatiotemporal manner. Glycosylation processes can be regulated by inhibition of glycosyltransferases or glycosidases that catalyze glycan assembly and synthesis (12, 13) .
Inhibitors of glycosyltransferases provide an important approach for studying glycosylation in cells, tissues, and whole organisms while avoiding some of the problems associated with studying protein mutants or gene silencing. Treatment of cells with inhibitors of glycosyltransferases results in the production of proteins containing missing or altered glycan chains, and thus allows us to examine the importance of endogenous glycans to specific cellular, tissue, or organ systems. Further, it provides an opportunity for designing drugs to treat diseases correlated with altered glycosylation.
B. Chemical Regulation of Glycosylation Processes
A number of inhibitors have been identified that interfere with glycoconjugates biosynthesis (6, (12) (13) (14) . Because the field is quite large, only a selection of inhibitors that act on specific enzymes or metabolic pathways and that illustrate certain basic concepts are discussed here. Specifically, this review summarizes recent developments in chemical regulation of glycosylation processes by inhibiting glycosyltransferases and glycosidases that are responsible for assembly, processing, and turnover of glycans in glycoproteins, proteoglycans, and glycolipids biosynthesis ( Table 2) .
B-1. Inhibition of N-Glycosylation
N-Glycosylation is one kind of common protein post-translational modification (PTM), in which the glycan is attached to an asparagine (N) located within a canonical sequence N-X-S/T (X, any amino acid except proline) (15) . N-Glycosylation begins in the ER and is continued throughout the Golgi apparatus (16) . 
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O-Glycosylation
GalNAc-α-Ser/Thr ppGALNTs Isoform specific Modified from Ref. (5) . 2 X cannot be Pro. 3 Repeat domains rich in Ser, Thr, Pro, Gly, Ala with no specific sequence. OGT: O-linked GlcNAc transferase;
OST: oligosaccharyltransferase; ppGALNTs: polypeptide GalNAc transferases; UGCG: UDP-glucose ceramide glucosyltransferase; XYLT: xylosyltransferase. Initially, the dolichol phosphate-dependent N-acetylglucosamine 1-phospho-transferase (DPAGT) catalyzes the transfer of GlcNAc from UDP-GlcNAc to dolichol phosphate to produce dolichol-PPGlcNAc. Then, another GlcNAc and five mannose residues are enzymatically added to the dolichol phosphate. Next, this dolichol-PP-oligosaccharide "flips" to the lumen side of the ER, where various enzymes add more mannoses and three glucoses to the existing glycan (15, 16) . Further, the oligosaccharide precursor is transferred onto the asparagine residue of the polypeptide chain. Next is the quality control "checkpoint", where three glucose residues are removed from the oligosaccharide by α-glycosidase I and II before leaving the ER. After entering the Golgi apparatus, the glycan is further modified to form different N-glycans, which are usually terminated with sialic acid and fucose moieties. All N-glycans contain a common sugar core comprising two GlcNAc and three mannose residues (Fig. 2) .
Inhibition of N-glycosylation is a useful approach to study Nglycoprotein structure, distribution and function (17) . Also, it is an important tool for examining the potential functional role(s) of Nglycans on specific proteins or intact cells. In general, treatment of cells with inhibitors of the enzymes that synthesize N-linked glycan chains results in the production of proteins containing missing or altered glycan chains. Several approaches have been used to prevent N-glycan assembly in N-glycoprotein biosynthesis. Mostly, they can be grouped to two approaches: (i) inhibition of dolichol-PP-GlcNAc assembly, which blocks glycosylation of glycoproteins Modified from Ref. (13, 14) . entirely and (ii) inhibition of glycan trimming reactions, which inhibits specific N-glycosylation processing steps.
B-1-1. Inhibition of Dolichol-PP-GlcNAc Assembly
N-Glycan biosynthesis can be terminated by inhibition of the first committed enzyme, DPAGT, which catalyzes the transformation from UDP-GlcNAc to GlcNAc-pyrophosphoryl-dolichol (Fig. 2) . Several DPAGT1 inhibitors have been identified to date.
Tunicamycin (1) was the first inhibitor of N-glycosylation discovered by Alan Elbein 40 years ago (18) . Tunicamycin (1) prevents protein N-glycosylation by inhibiting the formation of GlcNAcpyrophosphoryl-dolichol, which often leads to protein misfolding.
Nowadays, tunicamycin (1) is commonly used to induce the "unfolded protein response" or ER stress (19) . Amphomycin (2) is another antibiotic that inhibits the lipid-linked saccharide pathway by blocking the formation of dolichyl-phosphoryl-mannose. Other antibiotics that act at the lipid-level are flavomycin (3), tsushimycin (4), and diumycin (5) (Fig. 3) . Overall, these antibiotics have been widely used in a number of functional studies of N-glycosylation (6, 13, 17) .
B-1-2. Inhibition of Glycan Trimming Reactions
Removing monosaccharides from the nascent N-linked oligo- On the other hand, 1,1-deoxymannojirimycin (9) inhibits α-mannosidase I, a key enzyme for N-glycan processing in the Golgi (20) .
By inhibiting α-mannosidase I activity, the target protein will not generate N-linked oligosaccharides with complex and hybrid man- 
B-2. Inhibition of O-Glycosylation
O-Glycosylation is another type of common PTM, in which the glycan is attached to the protein via an oxygen atom on serine 
B-3. Inhibition of O-GlcNAc Modification
O-GlcNAc modification is another important PTM, which is
characterized by the linkage of a single β-GlcNAc to the hydroxyl group of Thr or Ser residues found in nuclear, cytoplasmic, and mitochondrial proteins (32) .
The addition of O-GlcNAc to proteins is catalyzed by O-GlcNAc transferase (OGT), and its removal is catalyzed by O-GlcNAcase (OGA). This dynamic O-GlcNAc glycosyl-
ation is analogous to phosphorylation and more than 1000 proteins have been described to be O-GlcNAcylated to date (33) .
The importance of O-GlcNAc addition to many cytoplasmic and nuclear proteins has stimulated great interest in developing agents to inhibit its addition by OGT or its removal by GlcNAcase (34) . Alloxan (20) is the first reported human OGT inhibitor, which is thought to inhibit OGT by binding to the uracil binding pocket or alternatively has been proposed to act through a covalent modification of cysteine residues (35) . Besides, xylosyltransferase-1/2, galactosyltransferase-1, galactosyltransfer-
Fig. 6. Inhibitors of O-GlcNAc transferase (OGT) (A) and O-GlcNAc hydrolase (OGA) (B).
ase-2, and glucuronyltransferase-1, respectively. From this linker tetrasaccharide, the sugar chains are extended by the addition of two alternating monosaccharides, an aminosugar and GlcA, catalyzed by glycosyltransferases: GalNAcT-I, GlcNAcT-I and GlcAT-II, respectively. In CS/DS, the aminosugar is GalNAc and in HS and heparin it is GlcNAc. The sequential glycosylation, epimerization and sulfation occur in the Golgi apparatus catalyzed by specific glycosyltransferases, epimerases, and sulfotransferases (Fig. 7) .
The extent of epimerization of GlcA to iduronic acid (IdoA) and the sulfation pattern of the disaccharide units distinguish CS from DS and HS from heparin.
The biological activities of proteoglycans often depend on the GAG side chain's interaction with other proteins (46, 47) . The ability to manipulate or inhibit GAG biosynthesis would allow for a better understanding of the functions of endogenous GAGs and proteoglycans as well (48, 49) . Several different biochemical approaches have been utilized to manipulate GAG biosynthesis (47).
Among them are two chemical approaches: (i) Xyloside primers,
targeting the linkage region as a starting place and also known as decoys for GAG biosynthesis, and (ii) GAG precursor utilization inhibitors, preventing GAG extension.
B-4-1. Xyloside Primers
Okayama et al. first found that p-nitrophenol β-D-xyloside
inhibited the assembly of GAGs on proteoglycans 43 years ago (50) . It was found that the xyloside mimics the natural substrate, xylosylated serine residues in proteoglycan core proteins, and thus acts as a substrate, which diverts the assembly process from the endogenous core proteins and causes inhibition of proteogly- (53). They also found that acetylated 1-propanoic fluorosamine (37) was effective at reducing CS synthesis in cultured astrocytes.
B-5. Inhibition of Glycolipid Biosynthesis
Glycolipids (Fig. 10) , also inhibits GlcCer synthase but shows no inhibition of α-glucosidase I and II in vitro (70) . NB-DNJ (42) and NB-DGJ (43) would be useful compounds for inhibiting gangliosides synthesis and studying their function.
B-6. Inhibition of Specific Glycosyltransferases of the Terminal Glycosylation Processes
Glycans are often terminated with specific sugars, like fucose, poly-N-acetyllatosamine and sialic acid. Due to their terminal locations, these sugars are closely involved in recognition processes of glycoconjugates in either physiological or pathological pathways.
Therefore, inhibition of the terminal glycan formation will provide a powerful approach for studying glycan and glycoconjugate function and may provide new therapeutic targets and mechanisms.
In this review, the recent approaches for regulation of terminal fucose, poly-N-acetyllatosamine and sialic acid attachment on either N-glycans or O-glycans are discussed briefly. There are several comprehensive reviews for each category reported recently (71) (72) (73) . The readers are recommended to these reviews for more detailed information and biomedical interests.
B-6-1. Inhibition of Fucosylation
L-Fucose often exists as a terminal sugar in glycoconjugate glycans that are essential for either physiological or pathological activities, such as inflammation, bacterial and viral infections, tumor metastasis, and genetic disorders (72) . Fucosyltransferases (58) (Fig. 11C) . Recently, Szabo and Skropeta published another review of the latest developments in ST inhibitors from design and high-throughput screening, addressing both the challenges and opportunities in targeting cell surface sialylation (74) . The review features an overview of the biological evaluation methods, computational and imaging tools, inhibitor molecular diversity, and selectivity toward ST subtypes, along with the emerging role of ST inhibitors as diagnostic tools for disease imaging (74) . Therefore, readers are recommended to refer these two comprehensive reviews (73, 74) for more detailed information.
C. Summary and Future Perspective
Glycoconjugates are ubiquitous biomolecules found in all kingdoms of life. The diverse structures of glycoconjugates are controlled by complex glycosylation process and are metabolically responsive and occur in a cell-and protein-specific manner, conferring tissue type-specific properties. They have essential roles in di- and that significant selectivity needs to be achieved for enzymes of a single family. In addition, there remains a pressing need for cellpermeable small molecule inhibitors that are amenable to chemical modification. Finally, the coordinated efforts of chemists, biochemists and biologists will be crucial for creating, characterizing and validating inhibitors that are useful tools both for advancing a basic understanding of glycobiology as well as for discovering new potential therapeutic targets and mechanisms for disease prevention and treatment.
